Award
National Cancer Institute 1R01CA315861-01
Individualized DNA junctions for glioma response assessment via longitudinal liquid biopsies
Recipient
Mayo Clinic Rochester
Award Amount
$565,423.00
Ceiling
$565,423.00
Awarded
July 24, 2026
Identifier
1R01CA315861-01
The award supports research to develop and validate individualized DNA junction assays as liquid biopsy biomarkers for monitoring glioma response, using CSF and plasma samples, including evaluation during CAR T therapy.
Description
This project aims to develop minimally invasive, patient-specific liquid biopsy biomarkers for glioma monitoring, utilizing cerebrospinal fluid (CSF) and plasma samples, and evaluating in the context of standard therapy and chimeric antigen receptor T-cell (CAR T) trials. The study focuses on establishing and validating DNA junction assays in longitudinal CSF samples as a candidate monitoring biomarker during standard-of-care therapy and in a trial of CAR T therapy for glioma patients.